Header cover image

Taiwanese (TAIEX) Healthcare Sector Analysis

UpdatedFeb 21, 2025
DataAggregated Company Financials
Companies215
  • 7D-1.6%
  • 3M4.4%
  • 1Y5.1%
  • YTD10.1%

Last week, the Healthcare industry hasn't moved much but Heron Neutron Medical is up 20% in that time. The past year has been better, since the industry has gained 6.5% in that time. Looking forward, earnings are forecast to grow by 52% annually.

Sector Valuation and Performance

Has the Taiwanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 21 Feb 2025NT$1.6tNT$246.5bNT$8.4b23.9x195.5x6.7x
Sun, 19 Jan 2025NT$1.5tNT$246.2bNT$8.7b21.9x174x6.2x
Tue, 17 Dec 2024NT$1.4tNT$220.5bNT$7.3b21.6x195x6.5x
Thu, 14 Nov 2024NT$1.5tNT$238.4bNT$7.4b23.7x203.6x6.3x
Sat, 12 Oct 2024NT$1.5tNT$236.4bNT$6.8b24.5x225.5x6.4x
Mon, 09 Sep 2024NT$1.6tNT$236.4bNT$6.8b25.1x232.7x6.7x
Wed, 07 Aug 2024NT$1.5tNT$229.2bNT$3.5b26.1x418x6.4x
Fri, 05 Jul 2024NT$1.7tNT$228.8bNT$3.6b28.9x463.4x7.3x
Sun, 02 Jun 2024NT$1.5tNT$228.6bNT$3.9b26x382x6.5x
Tue, 30 Apr 2024NT$1.5tNT$228.8bNT$4.3b25.8x342x6.4x
Thu, 28 Mar 2024NT$1.5tNT$228.9bNT$7.2b25.9x200.9x6.4x
Sat, 24 Feb 2024NT$1.5tNT$225.8bNT$6.5b25.3x224.9x6.4x
Mon, 22 Jan 2024NT$1.4tNT$225.0bNT$5.9b24.5x234.8x6.2x
Wed, 20 Dec 2023NT$1.4tNT$224.7bNT$5.9b25.4x239.5x6.3x
Fri, 17 Nov 2023NT$1.4tNT$224.0bNT$7.0b25x196.6x6.2x
Sun, 15 Oct 2023NT$1.3tNT$225.3bNT$8.3b24.9x162.9x6x
Tue, 12 Sep 2023NT$1.4tNT$225.2bNT$8.4b25x163x6.1x
Thu, 10 Aug 2023NT$1.4tNT$225.8bNT$10.9b26.1x129.6x6.3x
Sat, 08 Jul 2023NT$1.4tNT$226.5bNT$11.5b25.6x124.3x6.3x
Mon, 05 Jun 2023NT$1.4tNT$225.6bNT$12.2b24.3x117.8x6.4x
Wed, 03 May 2023NT$1.4tNT$220.1bNT$12.0b24.5x120.1x6.6x
Fri, 31 Mar 2023NT$1.4tNT$220.9bNT$12.4b21x115.7x6.5x
Sun, 26 Feb 2023NT$1.4tNT$214.6bNT$13.6b21.5x106.5x6.7x
Tue, 24 Jan 2023NT$1.3tNT$214.5bNT$13.8b20.1x94.3x6.1x
Thu, 22 Dec 2022NT$1.3tNT$214.5bNT$14.1b19.8x91.1x6x
Sat, 19 Nov 2022NT$1.3tNT$216.1bNT$15.8b17.5x80x5.8x
Mon, 17 Oct 2022NT$1.2tNT$207.4bNT$10.8b19x109.4x5.7x
Wed, 14 Sep 2022NT$1.4tNT$207.4bNT$10.7b21.7x133.4x6.9x
Fri, 12 Aug 2022NT$1.2tNT$200.4bNT$10.3b20.9x121x6.2x
Sun, 10 Jul 2022NT$1.2tNT$199.0bNT$9.8b22x121.1x5.9x
Tue, 07 Jun 2022NT$1.2tNT$207.9bNT$10.7b22.3x111.9x5.8x
Thu, 05 May 2022NT$1.2tNT$206.2bNT$12.3b22.3x99.9x5.9x
Sat, 02 Apr 2022NT$1.3tNT$204.2bNT$12.3b23.5x103x6.2x
Mon, 28 Feb 2022NT$1.2tNT$202.2bNT$14.2b22.5x84x5.9x
Price to Earnings Ratio

84x


Total Market Cap: NT$1.2tTotal Earnings: NT$14.2bTotal Revenue: NT$202.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Healthcare Sector Price to Earnings3Y Average 178.4x202320242025
Current Industry PE
  • Investors are optimistic on the Taiwanese Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 200x which is higher than its 3-year average PE of 178x.
  • The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 16% per year over the last three years.
  • Meanwhile revenues for these companies have grown 6.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare sector?

TW Market0.56%
Healthcare-1.59%
Healthtech6.88%
Medical Equipment5.37%
Life Sciences0.60%
Healthcare Services0.29%
Pharma-0.17%
Biotech-6.89%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 170x.
    • It looks like they are confident that earnings will grow faster in the future than they have historically.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 70% over the next 5 years.
  • This is better than its past earnings growth rate of 8.8% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
7799 Heron Neutron MedicalNT$389.5028.8%
+NT$12.1b
n/aPS228062.1x
6620 Handa PharmaceuticalsNT$90.3016.5%
+NT$1.8b
-48.1%PE28.2x
6541 Tanvex BioPharmaNT$78.109.4%
+NT$1.6b
25.0%PS454.2x
6949 Pell Bio-Med TechnologyNT$146.0012.3%
+NT$924.8m
n/aPS458.4x
6712 Ever Supreme Bio TechnologyNT$186.506.3%
+NT$897.2m
2.6%PE59.8x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6712

NT$186.50

Ever Supreme Bio Technology

7D

6.3%

1Y

2.6%

6550

NT$46.30

Polaris Group

7D

-9.0%

1Y

-34.3%

6620

NT$90.30

Handa Pharmaceuticals

7D

16.5%

1Y

-48.1%

4743

NT$81.60

Oneness Biotech

7D

-3.4%

1Y

-51.5%

6446

NT$640.00

PharmaEssentia

7D

-16.6%

1Y

97.5%

6919

NT$930.00

Caliway Biopharmaceuticals

7D

-1.3%

1Y

261.2%

6949

NT$146.00

Pell Bio-Med Technology

7D

12.3%

1Y

n/a

6541

NT$78.10

Tanvex BioPharma

7D

9.4%

1Y

25.0%

6472

NT$873.00

Bora Pharmaceuticals

7D

-3.5%

1Y

35.1%

6535

NT$235.00

Lumosa Therapeutics

7D

-4.5%

1Y

76.0%

6617

NT$116.50

Gongwin Biopharm Holdings

7D

-3.3%

1Y

-42.0%

3218

NT$234.00

Universal Vision Biotechnology

7D

2.9%

1Y

-21.6%

6782

NT$191.50

Visco Vision

7D

4.9%

1Y

-24.6%

1799

NT$67.80

Easywell Biomedicals

7D

7.6%

1Y

29.9%